Spectrum Pharma (SPPI) Tops Q1 EPS by 6c

Go back to Spectrum Pharma (SPPI) Tops Q1 EPS by 6c

Spectrum Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Update

May 13, 2021 4:00 PM EDT

Poziotinib NDA on track for 2021 submission

New poziotinib twice daily dosing (BID) data presented at AACR demonstrated improved anti-tumor activity and better tolerance

FDA pre-approval inspection at the ROLONTIS® manufacturing facility scheduled for May 2021

Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial... More